• Thursday, November 12, 2026 @ 12:00 am

Neurosterix Announces $105 Million Series B Financing and Appointments of Leading Neuropsychiatry Drug Development Executives

  • Financing led by RTW Investments supports planned advancement of NTX-253 into Phase 2 clinical development for schizophrenia
  • Andrew Miller, Founder of Karuna Therapeutics, appointed Executive Chair; Edmund Harrigan joins Board of Directors
  • Stephen Brannan, former Chief Medical Officer of Karuna Therapeutics, appointed Chair of Clinical Advisory Board

Neurosterix, a clinical-stage biotechnology company developing novel, selective allosteric modulators for neuropsychiatric disorders, announced the closing of a $105 million Series B financing. The round was led by RTW Investments with participation from new investors Janus Henderson Investors, GV, Ikarian Capital, Affinity Asset Advisors, and Dellora Investments alongside existing investors Perceptive Advisors and Acorn Bioventures.

Proceeds will primarily support the planned advancement of Neurosterix’s lead clinical-stage program, NTX-253, a highly selective muscarinic M4 positive allosteric modulator (PAM), into Phase 2 clinical development for schizophrenia. The financing will also support the company’s broader pipeline of selective allosteric modulators for a range of neuropsychiatric disorders.

In conjunction with the financing, Neurosterix announced three key leadership appointments: Andrew Miller, Ph.D., as Executive Chair of the Board of Directors; Edmund Harrigan, M.D., as an independent director; and, Stephen Brannan, M.D., as Chair of the Clinical Advisory Board. Each brings extensive experience in neuropsychiatric drug development, including senior leadership roles at Karuna Therapeutics, which pioneered a novel approach to treating schizophrenia through the development of COBENFY®, the first muscarinic-based therapy approved for the disease.

Advancing a differentiated approach to neuropsychiatric drug development
Neurosterix is developing highly selective allosteric modulators designed to regulate neural signaling pathways implicated in neuropsychiatric disorders. By fine-tuning receptor signaling rather than directly activating or blocking receptors, the company’s allosteric approach seeks to achieve more precise therapeutic effects with differentiated clinical profiles.

The company’s lead program, NTX-253, is a highly selective, brain-penetrant M4 PAM targeting the muscarinic M4 receptor, a clinically validated target in schizophrenia. Neurosterix has completed Phase 1 single- and multiple-ascending-dose clinical studies of NTX-253; data demonstrated a pharmacokinetic profile supportive of once-daily oral dosing. These findings support further clinical evaluation of NTX-253 as a potentially differentiated antipsychotic treatment option.

Expanding a pipeline of differentiated neuropsychiatric therapies
Beyond NTX-253, Neurosterix is advancing novel allosteric modulators targeting additional pathways. NTX-819, a potentially first-in-class negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), supported by preclinical findings in models related to stress, mood and aggression. Neurosterix is also developing NTX-529, a second differentiated M4 PAM for potential applications in additional psychosis- and mood-related disorders.

The company’s intellectual property portfolio includes more than 100 patent filings. Its discovery capabilities combine expertise in medicinal chemistry and receptor pharmacology with a proprietary library of more than 80,000 compounds and over 200 CNS-relevant functional assays to support the discovery and optimization of selective allosteric modulators addressing multiple therapeutic targets for high unmet medical needs.

Keep browsing

You may also be interested in